Opens in a new tab

New Prostate Cancer Screening Guidelines 2026: PSA Every 2 Years From Age 50

Table of Content

Prostate cancer screening guidelines: a man and his doctor review a PSA blood test result on a tablet in the clinic

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

For the first time since 2010, the American Cancer Society (ACS) has rewritten its prostate cancer screening guideline, and the change is a big one. On November 12, 2026, the ACS stopped treating the PSA blood test as something men should get only if they ask for it. The new guideline recommends regular PSA screening on a set schedule: every two years for most men aged 50 to 69, and every year from age 45 for men at higher risk.

The update was published in CA: A Cancer Journal for Clinicians. It also changes what should happen after a high result: a second PSA test first, then an MRI or another biomarker test before anyone talks about a biopsy. Here is what the new prostate cancer screening guidelines say, why they changed, and what they mean for your next blood test.

What the new ACS prostate cancer screening guidelines recommend

The ACS now sorts men into risk groups and gives each one an age range and a testing interval. Screening still starts with a conversation: clinicians are asked to make sure men understand the benefits, limits and possible harms before the first test, and men can stop at any point.

WhoWhen to startHow often
Men at average riskAge 50, through 69PSA every 2 years
Black menAge 45, through 69PSA every year
Strong family history (a father, brother or son diagnosed before 65, or several first-degree relatives)Age 45, through 69PSA every year
One first-degree relative diagnosed at 65 or olderAge 45, through 69PSA every 2 years
Men aged 70 to 74Individual decisionEvery 2 years if screening continues
Men 75 and older, or with a life expectancy under 10 yearsNot recommendedVery healthy men up to 79 with a rising PSA may continue after talking with their doctor

The previous ACS guideline, from 2010, did not set a schedule at all. It asked men and their doctors to make a shared decision, which in practice left many men who never brought it up untested.

A lower PSA cutoff and a two-step check before biopsy

The second big change concerns what counts as a high PSA and what happens next. For men aged 45 to 69, the guideline treats a PSA of 3.0 ng/mL or higher as elevated. For men aged 70 to 74, the cutoff is 6.5 ng/mL. That matters because many lab reports still flag only values above 4.0 ng/mL, so a result of 3.4 can look normal on paper while meeting the new definition of elevated.

An elevated result does not lead straight to a biopsy. The ACS asks for:

  • A repeat PSA test between two weeks and three months later, because PSA can rise for a while after an infection, an enlarged prostate, ejaculation or a long bike ride.
  • If the second result is still high, a prostate MRI and/or a validated biomarker test (blood or urine) to decide whether a biopsy is really needed.
  • For men found to have a low-risk cancer, active surveillance (regular monitoring) as the first option rather than immediate surgery or radiation.

The guideline does not favour any single biomarker test. For the basics of what the PSA number means, see our guide to the PSA (prostate-specific antigen) blood test.

Why the ACS changed its position now

Three lines of evidence pushed the update. First, the longest-running European screening trial showed, after more than two decades of follow-up, that inviting men to regular PSA tests keeps lowering deaths from prostate cancer, and that the balance between benefit and overdiagnosis has improved over time. Second, newer trials in Sweden and Finland showed that adding an MRI step after a high PSA spares many men a biopsy and cuts the diagnosis of harmless, slow-growing tumours. Third, active surveillance has become the standard way to handle low-risk cancers, which reduces the risk of overtreatment that made screening controversial in the first place.

According to the ACS, about 333,830 men in the United States will be diagnosed with prostate cancer in 2026 and about 36,320 will die from it, making it the second leading cause of cancer death in American men. Black men have a 67% higher incidence and nearly twice the death rate of White men, which is why the guideline starts them earlier and tests them every year.

How this compares with the USPSTF

The new ACS guideline goes further than the U.S. Preventive Services Task Force (USPSTF). The task force's current recommendation, from 2018, says PSA screening for men aged 55 to 69 should be an individual decision (grade C) and recommends against routine screening at 70 and older (grade D). The USPSTF has said an update is in progress. Its grades matter in practice because they decide which preventive services insurers must cover without cost sharing, so it is worth checking your plan before scheduling a PSA test on the new ACS timetable.

Which tests can monitor or screen for this?

  • Total PSA: the blood test at the heart of the new schedule. Ask for the actual number, not just "normal," and keep your past results so changes over time can be compared.
  • Repeat PSA: the confirmation step required before any further test when a first result is 3.0 ng/mL or higher.
  • Free PSA and the free-to-total PSA ratio: a lower ratio is more often linked to cancer than to benign enlargement.
  • Blood or urine biomarker panels (such as the 4Kscore, the Prostate Health Index or Stockholm3): used after a confirmed high PSA to estimate the risk of a significant cancer.
  • Prostate MRI: an imaging step that helps decide whether a biopsy is needed and where to target it.

Other tumour markers have very different uses; our overview of tumour markers explains why none of them replaces PSA for the prostate.

Recent advances in prostate cancer screening

  • The European screening trial now has 23 years of follow-up. It confirms that regular PSA testing prevents deaths from prostate cancer over the long run, and that fewer men need to be screened and diagnosed to prevent each death than earlier analyses suggested.
  • A large Swedish trial found that when men with a high PSA have a biopsy only if their MRI looks suspicious, more than half of the diagnoses of harmless cancers disappear, without a noticeable rise in serious cancers being missed.
  • A Finnish trial tested a full chain of PSA, then a blood biomarker panel, then MRI. It found mostly significant cancers and few harmless ones, which shows how a step-by-step approach can limit overdiagnosis.
  • An updated Cochrane review (2026), which pools all major randomized trials, now concludes that PSA screening likely reduces deaths from prostate cancer, a change from its 2013 conclusion.
  • In a racially and ethnically diverse U.S. group of men referred for biopsy, the Stockholm3 blood test identified significant cancers better than the free-to-total PSA ratio and could avoid many unnecessary biopsies.

Blood tests for prostate cancer risk keep evolving: read about the proteins found in blood samples taken 15 years before diagnosis.

When to see a doctor

  • You are 50 or older (45 or older if you are Black or have a close relative with prostate cancer) and have never discussed PSA screening.
  • Your PSA is 3.0 ng/mL or higher, even if the lab marks it as normal.
  • Your PSA has risen noticeably compared with your previous result.
  • You notice blood in your urine or semen, trouble urinating, or new, persistent pain in the lower back, hips or pelvis. These symptoms need a doctor's appointment whatever your age or screening schedule.

Learn more about the disease itself in our guide to prostate cancer.

Glossary

  • PSA (prostate-specific antigen): a protein made by the prostate and measured in a blood sample, in nanograms per millilitre (ng/mL).
  • Overdiagnosis: finding a cancer that would never have caused symptoms or shortened a man's life.
  • Active surveillance: close monitoring of a low-risk cancer with regular PSA tests, MRI and sometimes biopsies, with treatment only if it progresses.
  • Biomarker test: a blood or urine test that combines several measurements to estimate the risk of a significant cancer.
  • First-degree relative: a father, brother or son.
  • USPSTF: the U.S. Preventive Services Task Force, an independent panel whose screening grades shape insurance coverage.

FAQ

At what age should I start PSA screening under the new guidelines?

At 50 for men at average risk, and at 45 for Black men and men with a father, brother or son who had prostate cancer. Screening generally stops at 75, earlier if life expectancy is under 10 years.

How often should I get a PSA test?

Every two years for most men aged 50 to 69. Every year for Black men and men with a strong family history, from 45 to 69.

What PSA level is considered high now?

3.0 ng/mL or higher for men aged 45 to 69, and 6.5 ng/mL or higher for men aged 70 to 74. A single high value should be confirmed by a second test.

Does a high PSA mean I need a biopsy?

Not right away. The guideline recommends repeating the test, then using an MRI and/or a biomarker test to decide whether a biopsy is useful.

Will my insurance cover a PSA test every two years?

Coverage depends on your plan. Insurers follow the USPSTF, whose 2018 recommendation is still in force while an update is underway, so ask your insurer before testing.

Sources

Other articles

Understand your own blood test results with AI DiagMe

Got a PSA result, or a full blood panel, and not sure what the numbers mean? Upload your lab report to AI DiagMe and get a clear, personalized explanation of every value in minutes, to prepare the conversation with your doctor.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practising hospital physicians in specialties such as haematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr Claude Tchonko is a haematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specialises in the management of haematological malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimisation of care pathways in onco-haematology.

    Author of a reference work, ‘Lymphoid Haematological Malignancies in Mali’, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Haematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Haematology and an inter-university diploma (DIU) in Onco-Haematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming soon